Literature DB >> 10725626

Radiosurgery for brain metastases: a score index for predicting prognosis.

E Weltman1, J V Salvajoli, R A Brandt, R de Morais Hanriot, F E Prisco, J C Cruz, S R de Oliveira Borges, D B Wajsbrot.   

Abstract

PURPOSE: To analyze a prognostic score index for patients with brain metastases submitted to stereotactic radiosurgery (the Score Index for Radiosurgery in Brain Metastases [SIR]). METHODS AND MATERIALS: Actuarial survival of 65 brain metastases patients treated with radiosurgery between July 1993 and December 1997 was retrospectively analyzed. Prognostic factors included age, Karnofsky performance status (KPS), extracranial disease status, number of brain lesions, largest brain lesion volume, lesions site, and receiving or not whole brain irradiation. The SIR was obtained through summation of the previously noted first five prognostic factors. Kaplan-Meier actuarial survival curves for all prognostic factors, SIR, and recursive partitioning analysis (RPA) (RTOG prognostic score) were calculated. Survival curves of subsets were compared by log-rank test. Application of the Cox model was utilized to identify any correlation between prognostic factors, prognostic scores, and survival.
RESULTS: Median overall survival from radiosurgery was 6.8 months. Utilizing univariate analysis, extracranial disease status, KPS, number of brain lesions, largest brain lesion volume, RPA, and SIR were significantly correlated with prognosis. Median survival for the RPA classes 1, 2, and 3 was 20.19 months, 7.75 months, and 3. 38 months respectively (p = 0.0131). Median survival for patients, grouped under SIR from 1 to 3, 4 to 7, and 8 to 10, was 2.91 months, 7.00 months, and 31.38 months respectively (p = 0.0001). Using the Cox model, extracranial disease status and KPS demonstrated significant correlation with prognosis (p = 0.0001 and 0.0004 respectively). Multivariate analysis also demonstrated significance for SIR and RPA when tested individually (p = 0.0001 and 0.0040 respectively). Applying the Cox Model to both SIR and RPA, only SIR reached independent significance (p = 0.0004).
CONCLUSIONS: Systemic disease status, KPS, SIR, and RPA are reliable prognostic factors for patients with brain metastases submitted to radiosurgery. Applying SIR and RPA classifications to our patients' data, SIR demonstrated better accuracy in predicting prognosis. SIR should be further tested with larger patient accrual and for all patients with brain metastases subjected or not to stereotactic radiosurgery.

Entities:  

Mesh:

Year:  2000        PMID: 10725626     DOI: 10.1016/s0360-3016(99)00549-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  96 in total

Review 1.  Whole-brain radiation therapy in breast cancer patients with brain metastases.

Authors:  Cyrus Chargari; François Campana; Jean-Yves Pierga; Lionel Védrine; Damien Ricard; Sylvestre Le Moulec; Alain Fourquet; Youlia M Kirova
Journal:  Nat Rev Clin Oncol       Date:  2010-07-13       Impact factor: 66.675

2.  Brain metastases in patients under 50 years of age: retrospective analysis.

Authors:  Carsten Nieder; Anca L Grosu; Oddvar Spanne; Nicolaus H Andratschke; Hans Geinitz
Journal:  Clin Exp Metastasis       Date:  2012-05-27       Impact factor: 5.150

3.  Perilesional edema in brain metastasis from non-small cell lung cancer (NSCLC) as predictor of response to radiosurgery (SRS).

Authors:  Paolo Tini; Valerio Nardone; Pierpaolo Pastina; Giuseppe Battaglia; Claudia Vinciguerra; Tommaso Carfagno; Giovanni Rubino; Salvatore Francesco Carbone; Lucio Sebaste; Alfonso Cerase; Antonio Federico; Luigi Pirtoli
Journal:  Neurol Sci       Date:  2017-03-04       Impact factor: 3.307

Review 4.  State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer.

Authors:  Alessandro Inno; Vincenzo Di Noia; Ettore D'Argento; Alessandra Modena; Stefania Gori
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 5.  Radiosurgery in the treatment of brain metastases: critical review regarding complications.

Authors:  Marcos Vinícius Calfat Maldaun; Paulo Henrique Pires Aguiar; Frederick Lang; Dima Suki; David Wildrick; Raymond Sawaya
Journal:  Neurosurg Rev       Date:  2007-10-24       Impact factor: 3.042

Review 6.  Systemic therapy of brain metastases.

Authors:  Harry C Brastianos; Daniel P Cahill; Priscilla K Brastianos
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

7.  Novel graded prognostic assessment for colorectal cancer patients with brain metastases.

Authors:  Byoung Hyuck Kim; Hae Jin Park; Kyubo Kim; Sae-Won Han; Tae-You Kim; Seung-Yong Jeong; Kyu Joo Park; Eui Kyu Chie
Journal:  Int J Clin Oncol       Date:  2018-08-03       Impact factor: 3.402

8.  The treatment of patients with 1-3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis.

Authors:  Michela Buglione; Sara Pedretti; Stefano Gipponi; Luciano Buttolo; Paolo Panciani; Pietro Luigi Poliani; Roberto Liserre; Paolo Borghetti; Ludovica Pegurri; Loredana Costa; Luca Triggiani; Nadia Pasinetti; Paolo Ghirardelli; Sara Pandini; Alessandro Padovani; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2015-04-28       Impact factor: 3.469

9.  Validity of two recently-proposed prognostic grading indices for lung, gastro-intestinal, breast and renal cell cancer patients with radiosurgically-treated brain metastases.

Authors:  Masaaki Yamamoto; Toru Serizawa; Yasunori Sato; Takuya Kawabe; Yoshinori Higuchi; Osamu Nagano; Bierta E Barfod; Junichi Ono; Hidetoshi Kasuya; Yoichi Urakawa
Journal:  J Neurooncol       Date:  2012-12-09       Impact factor: 4.130

10.  Type and timing of systemic therapy use predict overall survival for patients with brain metastases treated with radiation therapy.

Authors:  Kevin Yijun Fan; Nafisha Lalani; Nathalie LeVasseur; Andra Krauze; Fred Hsu; Lovedeep Gondara; Kaylie Willemsma; Alan McVey Nichol
Journal:  J Neurooncol       Date:  2020-11-18       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.